返回 
加入收藏
雾化吸入布地奈德对急性支气管炎患者疗效及相关指标的影响
x
请在关注微信后，向客服人员索取文件
| 篇名： | 雾化吸入布地奈德对急性支气管炎患者疗效及相关指标的影响 |
| TITLE： | |
| 摘要： | 目的：探讨雾化吸入布地奈德对急性支气管炎患者疗效及相关指标的影响。 方法：102例急性支气管炎患者随机均分为对照组和观察组。对照组患者给予头孢噻肟钠注射液100 mg/（kg·d），加入0.9％氯化钠注射液150 ml中分2次静脉滴注，同时给予镇静、吸氧、补液及纠正酸碱平衡等常规治疗；观察组患者在对照组治疗的基础上雾化吸入布地奈德混悬液2 ml，每日2次。两组疗程均为7 d。观察两组患者的临床疗效，治疗前后红细胞免疫复合物花环率（E-ICR）、超敏C反应蛋白（hs-CRP）、呼吸峰流速（PEF）、用力肺活量（FVC）、1 s用力呼出量（FEV1），体温恢复正常时间、咳嗽消失时间、啰音消失时间及不良反应发生情况。结果：观察组患者总有效率显著高于对照组，体温恢复正常时间、咳嗽消失时间、啰音消失时间均显著短于对照组，差异均有统计学意义（P＜0.05）。治疗前，两组患者E-ICR、hs-CRP、PEF、FVC、FEV1比较，差异均无统计学意义（P＞0.05）。治疗后，两组患者E-ICR、hs-CRP均显著低于同组治疗前，且观察组低于对照组，PEF、FVC、FEV1均显著高于同组治疗前，且观察组高于对照组，差异均有统计学意义（P＜0.05）。两组患者治疗期间均未见明显不良反应发生。结论：在常规治疗的基础上，雾化吸入布地奈德治疗急性支气管炎的疗效显著，可降低E-ICR、hs-CRP，改善肺功能，且安全性较好。 |
| ABSTRACT： | OBJECTIVE：To explore the effects of inhaled budesonide on the efficacy and related indexes of patients with acute bronchitis. METHODS： 102 patients with acute bronchitis were randomly divided into control group and observation group. Control group was given 100 mg/（kg·d） Cefotaxime sodium injection， adding into 150 ml 0.9％ Sodium chloride injection intravenously by 2 times， as well as sedation， oxygen inhalation， rehydration， correcting acid-base balance and other conventional treatment； observation group was additionally given 2 ml Inhaled budesonide suspension， twice a day. The treatment course for both groups was 7 d. Clinical efficacy， erythrocyte immune complex rosette （E-ICR）， high-sensitivity C-reactive protein （hs-CRP）， peak expiratory flow rate （PEF）， forced vital capacity （FVC）， 1 second forced exhaled volume （FEV1）， time of body temperature returned to normal， cough disappearance time， rale disappearance time before and after treatment， and incidence of adverse reactions in 2 groups were observed. RESULTS： The total effective rate in observation group was significantly higher than control group， time of body temperature returned to normal， cough disappearance time and rale disappearance time were significantly shorter than control group， the differences were statistically significant （P＜0.05）. Before treatment， there were no significant differences in the E-ICR and hs-CRP levels， PEF， FVC and FEV1 between 2 groups （P＞0.05）. After treatment， E-ICR and hs-CRP levels were significantly lower than before， and observation group was lower than control group， PEF， FVC and FEV1 were significantly higher than before， and observation group was higher than control group， the differences were statistically significant （P＜0.05）. And there were no adverse reactions during treatment. CONCLUSIONS： Based on conventional treatment， inhaled budesonide has obvious efficacy in the treatment of acute bronchitis， and it can reduce E-ICR and hs-CRP， improve pulmonary functions， with good safety. |
| 期刊： | 2016年第27卷第12期 |
| 作者： | 余林，孙健，何杰，杨凯，杨帆，方恩荣，马春兰 |
| AUTHORS： | YU Lin，SUN Jian，HE Jie，YANG Kai，YANG Fan，FANG Enrong，MA Chunlan |
| 关键字： | 布地奈德；急性支气管炎；红细胞免疫复合物花环率；超敏C反应蛋白；肺功能；疗效；安全性 |
| KEYWORDS： | Budesonide； Acute bronchitis； E-ICR； hs-CRP； Pulmonary function； Efficacy； Safety |
| 阅读数： | 533 次 |
| 本月下载数： | 5 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
